This is a Proprietary Laboratory Analyses (PLA) code, meaning that the code applies to only one unique lab test made by a specific manufacturer or performed by a specific lab. Report 0340U only for Signatera™ from Natera Inc. The test uses a cancer patient’s plasma specimen for a targeted sequence analysis using circulating tumor DNA (ctDNA). The targeted DNA is based on a prior next–generation sequence (NGS) analysis of the patient’s tumor and germline (inherited) DNA for a customized evaluation of minimal residual disease (MRD).
For clinical responsibility, terminology, tips and additional info
start codify free trial.